Mulcrone, Patrick L.Herzog, Roland W.Xiao, Weidong2023-09-082023-09-082022-10-02Mulcrone PL, Herzog RW, Xiao W. Adding recombinant AAVs to the cancer therapeutics mix. Mol Ther Oncolytics. 2022;27:73-88. Published 2022 Oct 2. doi:10.1016/j.omto.2022.09.009https://hdl.handle.net/1805/35478Gene therapy is a powerful biological tool that is reshaping therapeutic landscapes for several diseases. Researchers are using both non-viral and viral-based gene therapy methods with success in the lab and the clinic. In the cancer biology field, gene therapies are expanding treatment options and the possibility of favorable outcomes for patients. While cellular immunotherapies and oncolytic virotherapies have paved the way in cancer treatments based on genetic engineering, recombinant adeno-associated virus (rAAV), a viral-based module, is also emerging as a potential cancer therapeutic through its malleability, specificity, and broad application to common as well as rare tumor types, tumor microenvironments, and metastatic disease. A wide range of AAV serotypes, promoters, and transgenes have been successful at reducing tumor growth and burden in preclinical studies, suggesting more groundbreaking advances using rAAVs in cancer are on the horizon.en-USAttribution-NonCommercial-NoDerivatives 4.0 InternationalGene therapyrAAVCancerTumor microenvironmentTissue tropismAAV designArticle